Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

→ An­oth­er cut of pos­i­tive in­ter­im da­ta have lift­ed ex­pec­ta­tions that Ad­verum’s gene ther­a­py that could give the an­ti-VEGF de­vel­op­ers … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

DBV Tech­nolo­gies has all but so­lid­i­fied its run­ner up sta­tus in the race to bring a peanut al­ler­gy treat­ment on to the Unit­ed States mar­ket … ...

Just hours af­ter J&J’s on­col­o­gy team bragged about scor­ing a break­through ther­a­py des­ig­na­tion for their BC­MA CAR-T drug, they pulled the wraps off of the mul­ti­ple myelo­ma da­ta for ...

The Fed­er­al Trade Com­mis­sion wants more in­for­ma­tion on Pfiz­er’s takeover of Seagen be­fore it will make a rul­ing on whether it will clear the … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

With the pan­dem­ic po­ten­tial­ly en­ter­ing its lat­er stages, ma­jor drug­mak­ers like Mer­ck have jumped in to aid in the gar­gan­tu­an task of man­u­fac­tur­ing oth­er … ...

A whole in­dus­try may have been born out of the spec­tac­u­lar suc­cess of CD19 CAR-T, push­ing the en­ve­lope on next-gen­er­a­tion con­structs hit­ting new tar­gets. But … ...

The FDA forced Acel­Rx Phar­ma­ceu­ti­cals to go back to the draw­ing board to re­fash­ion a bet­ter safe­ty plan for its new pain ther­a­py Dsu­via … ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

HHS and FDA on Fri­day said they’re with­draw­ing a no­tice pub­lished just days be­fore for­mer Pres­i­dent Don­ald Trump left of­fice, which would’ve re­quired the FDA … ...